Huber Capital Management LLC Has $20.73 Million Stake in Pfizer Inc. $PFE

Huber Capital Management LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 813,518 shares of the biopharmaceutical company’s stock after acquiring an additional 45,000 shares during the quarter. Pfizer comprises about 3.3% of Huber Capital Management LLC’s investment portfolio, making the stock its 7th largest holding. Huber Capital Management LLC’s holdings in Pfizer were worth $20,728,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Norges Bank acquired a new stake in shares of Pfizer in the 2nd quarter valued at $2,270,157,000. Vanguard Group Inc. raised its position in shares of Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after purchasing an additional 10,198,330 shares during the period. Franklin Resources Inc. grew its position in Pfizer by 47.8% in the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after purchasing an additional 8,108,887 shares during the period. Neuberger Berman Group LLC raised its position in Pfizer by 203.8% in the third quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company’s stock worth $229,346,000 after acquiring an additional 6,045,763 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in shares of Pfizer by 43.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock worth $453,747,000 after purchasing an additional 5,662,309 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.4%

Shares of NYSE:PFE traded up $0.11 on Friday, hitting $26.97. 2,403,469 shares of the company’s stock were exchanged, compared to its average volume of 46,102,480. The business’s 50 day simple moving average is $26.47 and its two-hundred day simple moving average is $25.51. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The stock has a market capitalization of $153.34 billion, a price-to-earnings ratio of 19.85 and a beta of 0.47. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the prior year, the company posted $0.63 earnings per share. The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large market and adding a growth avenue beyond COVID products. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Early Phase‑2 data for trispecific antibody tilrekimig showed meaningful eczema improvement with a favorable safety profile — a successful later‑stage outcome could materially expand Pfizer’s immunology franchise. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer launched a new early‑stage oncology trial for PF‑07994525, extending its cancer pipeline and showing continued R&D investment that could produce longer‑term revenue drivers. Pfizer Advances Early‑Stage Cancer Candidate PF‑07994525
• Positive Sentiment: Completed Phase‑2 toddler study for Pfizer’s next‑gen pneumococcal vaccine advances that program toward later‑stage trials and potential label expansion. Pfizer Advances Next‑Gen Pneumococcal Vaccine
• Positive Sentiment: Scotiabank reiterated a Buy rating on Pfizer, which may support investor confidence and act as a near‑term positive catalyst for the stock. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Analyst/outlet coverage highlights Pfizer’s high dividend yield (~6.5%) and deep discount from prior highs, framing the stock as an income/value play for long‑term investors. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Neutral Sentiment: Industry coverage and commentary (health‑care roundups) mention Pfizer alongside peers — useful context but not an immediate stock mover. Health Care Roundup: Market Talk
• Neutral Sentiment: Pfizer commentary on navigating regulatory uncertainty (company expert piece) underlines the firm’s focus on compliance but has limited immediate market impact. Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials
• Negative Sentiment: Market reports show Pfizer’s share price dipped more than the broader market in recent sessions, reflecting short‑term selling pressure and investor caution. Pfizer (PFE) Sees a More Significant Dip Than Broader Market
• Negative Sentiment: Duplicate market‑movement coverage highlights the intraday weakness and may reinforce momentum selling. Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know
• Negative Sentiment: Competitive pressure: Bristol Myers’ deep late‑stage pipeline coverage reminds investors that peer advancements could divert future market share and investor attention away from Pfizer’s franchises. Is Bristol Myers’ Deep Pipeline the Key to Future Growth?

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Royal Bank Of Canada assumed coverage on Pfizer in a research report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price target on the stock. Scotiabank began coverage on shares of Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Bank of America cut their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research note on Thursday, February 12th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $28.05.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.